Cancer Chemotherapy and Pharmacology

, Volume 66, Issue 1, pp 89–94

Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer

  • Norikazu Masuda
  • Takahiro Nakayama
  • Jun Yamamura
  • Shunji Kamigaki
  • Tetsuya Taguchi
  • Mai Hatta
  • Junichi Sakamoto
Original Article



Although anthracycline is a key agent in breast cancer treatment, its use is associated with the risk of cardiotoxicity. Recently, the value of combination therapy with docetaxel and cyclophosphamide was reported. Because the characteristics of paclitaxel differ on weekly versus tri-weekly administration, such as in the induction of apoptosis and anti-angiogenic activity, establishment of a treatment regimen with a combination of paclitaxel and cyclophosphamide (PC) is warranted. We initiated a phase I study to determine the maximum tolerated dose (MTD) and recommended dose (RD) of combination therapy with PC for advanced or recurrent breast cancer.

Patients and methods

Eligible patients had advanced or recurrent breast cancer. Paclitaxel was given intravenously on days 1, 8, and 15 of every 3-week course, and cyclophosphamide on day 1, over a total of four courses. Paclitaxel was given at 80 mg/m2 for level 1 and 100 mg/m2 for level 2, and cyclophosphamide at 600 mg/m2 in both cases. Onset of dose-limiting toxicity was evaluated during the first course, and tolerability throughout the four courses.


Four patients were enrolled in each of levels 1 and 2 from October 2006 to November 2007. The main toxicities were grade 3 neutropenia in four patients (50%) and sensory neuropathy in one (12.5%). An MTD was not attained, as neither a hematologic toxicity of grade 4 nor a non-hematologic toxicity of grade 3 or higher was observed during the first course at level 1 or 2. Response rate amongst assessable patients (one in level 1, two in level 2) was 66.7%.


Safety was well tolerated throughout the four courses at level 2, and this dosage level was therefore regarded as the RD.


Breast cancer Combination chemotherapy Weekly paclitaxel Cyclophosphamide Phase I 


  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352:930–942CrossRefGoogle Scholar
  2. 2.
    Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK (2008) New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100:1058–1067CrossRefPubMedGoogle Scholar
  3. 3.
    Giordano SH (2006) 2006 ASCO annual meeting (abstract #521)Google Scholar
  4. 4.
    Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858–1867PubMedGoogle Scholar
  5. 5.
    Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10967 multicenter phase III trial. J Clin Oncol 20:3114–3121CrossRefPubMedGoogle Scholar
  6. 6.
    Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C, Central and Eastern Europe, Israel Paclitaxel Breast Cancer Study Group (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707–1715PubMedGoogle Scholar
  7. 7.
    Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, Shibata HR, Baez L, DeFusco PA, Davila E, Tipping SJ, Bearden JD, Thirlwell MP (1999) Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17:3403–3411PubMedGoogle Scholar
  8. 8.
    Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542–5551CrossRefPubMedGoogle Scholar
  9. 9.
    Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J, 303 Study Group (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341–2354PubMedGoogle Scholar
  10. 10.
    Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592CrossRefPubMedGoogle Scholar
  11. 11.
    Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R (1999) Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17:2355–2364PubMedGoogle Scholar
  12. 12.
    Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671CrossRefPubMedGoogle Scholar
  13. 13.
    Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642–1649CrossRefPubMedGoogle Scholar
  14. 14.
    Verrill MW, Lee J, Cameron DA (2007) Anglo-Celtic IV: first results of a UK National Research Network randomized phase III pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). In: 2007 ASCO annual meeting (abstract #LBA1005)Google Scholar
  15. 15.
    Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387CrossRefPubMedGoogle Scholar
  16. 16.
    Matsunami N, Masuda N, Morimoto T, Nakayama T, Nomura T, Ishitobi M, Kamigaki S, Yamamura J, Tsukamoto F, Ohashi Y, Taguchi T, Tsujinaka T (2008) Feasibility study of combination therapy with docetaxel and cyclophosphamide for breast cancer in Japan (in Japanese). In: 16th Annual meeting of the Japanese breast cancer society (abstract #O-217)Google Scholar
  17. 17.
    Pagani O, Sessa C, Martinelli G, Cerny T, de Jong J, Goldhirsch A, Zimatore M, Cavalli F (1997) Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol 8:655–661CrossRefPubMedGoogle Scholar
  18. 18.
    Tolcher AW, Cowan KH, Noone MH, Denicoff AM, Kohler DR, Goldspiel BR, Barnes CS, McCabe M, Gossard MR, Zujewski J, O’Shaughnessy JA (1996) Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 14:95–102PubMedGoogle Scholar
  19. 19.
    Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Sartorius S, Chen TL, Bowling K, Rowinsky EK (1996) Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14:783–791PubMedGoogle Scholar
  20. 20.
    Sessa C, Pagani O, Martinelli G, Cerny T, de Jong J, Goldhirsch A, Zimatore M, Cavalli F (1997) Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer. Semin Oncol 24(suppl 17):S17–52–S17–57Google Scholar
  21. 21.
    Nokihara H, Tamura T, Matsumoto Y (2002) Weekly paclitaxel in solid tumor, a phase I trial. 43rd The Japan Lung Cancer Society annual meeting (abstract #E-13). Jpn J Lung Cancer 42:395 (in Japanese)Google Scholar
  22. 22.
    Shulman L (2009) Phase III randomized study of adjuvant cyclophosphamide and doxorubicin versus single-agent paclitaxel in women with operable breast cancer and 0–3 positive axillary lymph nodes. Accessed 26 Aug 2009
  23. 23.
    Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L (1996) Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88:1308–1314CrossRefPubMedGoogle Scholar
  24. 24.
    Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843–1849PubMedGoogle Scholar
  25. 25.
    Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F (2000) Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 6:4610–4617PubMedGoogle Scholar
  26. 26.
    Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59:3776–3782PubMedGoogle Scholar
  27. 27.
    Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ (1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55:3564–3568PubMedGoogle Scholar
  28. 28.
    Eniu A, Palmieri FM, Perez EA (2005) Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10:665–685CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Norikazu Masuda
    • 1
  • Takahiro Nakayama
    • 2
  • Jun Yamamura
    • 1
  • Shunji Kamigaki
    • 3
  • Tetsuya Taguchi
    • 2
  • Mai Hatta
    • 4
  • Junichi Sakamoto
    • 4
  1. 1.Breast Oncology Group, Department of SurgeryOsaka National HospitalOsakaJapan
  2. 2.Department of Breast and Endocrine Surgery, Graduate School of MedicineOsaka UniversitySuitaJapan
  3. 3.Department of SurgerySakai Municipal HospitalSakaiJapan
  4. 4.Social Life Science, Young Leaders’ Program, Graduate School of MedicineNagoya UniversityNagoyaJapan

Personalised recommendations